… Vaccination in patients with hematological malignancies is complex as the background and
… states differ between different patient categories. Patients undergoing allogeneic HSCT are …

… generate potent immune responses that translate into clinically meaningful improvements
in outcomes for patients with hematological malignancies. The ability to selectively target the …

… in vaccinated patients with hematologic malignancies (HM). We performed a retrospective
cohort study of patient electronic health records of 514,413 fully vaccinated patients from 63 …

… on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti–severe …
-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and …

… vaccination on COVID-19 disease incidence and outcomes in patients with hematologic
malignancies … vaccination to higher risk for breakthrough infection, hospitalization, and death in …

… , but the ability to mount a protective immune response after vaccination … strategies for patients
with hematologic malignancies, … on vaccine responses after alemtuzumab in patients with …

… 14 days between vaccination and sampling (three patients and one control). Therefore, 423
subjects are included in this analysis: 315 patients with hematologic malignancies and 108 …

… in the field of hematology have recommended severe acute … -2) vaccination for all patients
with hematologic malignancies … -2 vaccination in patients with hematologic malignancies and …

… In our opinion, in patients with lymphadenopathy occurring after vaccination, it is important
to monitor the spontaneously regressive character of these lesions through regular clinical …

… to COVID-19 vaccination in patients with hematologic malignancies to build the … ie,
vaccine-induced immune response) of COVID-19 vaccines in patients with hematologic …